N/A
N=16
Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine
Growth Hormone Treatment · Aging
Bottom Line
View on ClinicalTrials.gov: NCT02987868 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Feb 2018
Primary outcome: Primary: Percent Change of Triiodthyronine Over Baseline — -3.3; -6.1 percent change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Amino acid supplement first day (Drug); Placebo first day (Drug); Amino acid supplement second day (Drug); Placebo second day (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Pennington Biomedical Research Center
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change of Triiodthyronine Over Baseline |
-3.3; -6.1 | — |
Summary
In a recent randomized, double-blind, cross-over clinical trial, serum growth hormone (hGH) increased 682% above baseline 120 minutes after oral administration of an amino acid-based dietary supplement (SeroVital), p=0.01 vs placebo. In contrast to the mechanism of hGH stimulation by ghrelin, the investigators hypothesize that the supplement suppresses somatostatin, a know inhibitor of both hGH and TSH. To test this hypothesis, the investigators measured triiodothyronine (T3) after administration of the amino acid-base supplement.
Eligibility Criteria
Inclusion Criteria
- 12 healthy males and 4 healthy females
- Between 18 and 70 years
Exclusion Criteria
- Pregnant or nursing
- Taking any chronic medication including birth control pills.
Data sourced from ClinicalTrials.gov (NCT02987868). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.